JACC:血流储备分数在稳定缺血性心脏病患者中的应用价值

2020-02-17 不详 MedSci原创

血流储备分数(FFR)在稳定缺血性心脏病(SIHD)中的测量和对预后的预测尚存争议。本研究的目的旨在评估FFR在现实世界中SIHD患者的预后预测中的应用。本研究纳入分析了来自66个医学中心的17989名经冠脉造影证实的SIHD患者,在轻中度病变的患者中,FFR的范围为14.8%-18.5%,而接受经皮冠脉介入治疗患者的FFR范围为44%-75%。FFR指导下的治疗患者的1年死亡率为2.8%,而仅由

血流储备分数(FFR)在稳定缺血性心脏病(SIHD)中的测量和对预后的预测尚存争议。本研究的目的旨在评估FFR在现实世界中SIHD患者的预后预测中的应用。

本研究纳入分析了来自66个医学中心的17989名经冠脉造影证实的SIHD患者,在轻中度病变的患者中,FFR的范围为14.8%-18.5%,而接受经皮冠脉介入治疗患者的FFR范围为44%-75%。FFR指导下的治疗患者的1年死亡率为2.8%,而仅由血管造影指导治疗患者的1年死亡率为5.9%(p < 0.0001)。经调整分析后,与血管造影指导相比,FFR指导下的血运重建可以降低患者43%的1年死亡风险。

研究结果显示,在稳定缺血性心脏病患者中,血流储备分数的使用率略有增加,且与患者1年死亡风险的降低相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893264, encodeId=42841893264c0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 25 12:48:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854649, encodeId=07c8185464967, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 05 19:48:00 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318378, encodeId=c90813183e8df, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326479, encodeId=b5ab13264e9c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379358, encodeId=b4c83e9358e2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 17 21:45:45 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893264, encodeId=42841893264c0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 25 12:48:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854649, encodeId=07c8185464967, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 05 19:48:00 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318378, encodeId=c90813183e8df, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326479, encodeId=b5ab13264e9c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379358, encodeId=b4c83e9358e2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 17 21:45:45 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2021-01-05 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893264, encodeId=42841893264c0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 25 12:48:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854649, encodeId=07c8185464967, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 05 19:48:00 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318378, encodeId=c90813183e8df, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326479, encodeId=b5ab13264e9c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379358, encodeId=b4c83e9358e2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 17 21:45:45 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893264, encodeId=42841893264c0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 25 12:48:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854649, encodeId=07c8185464967, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 05 19:48:00 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318378, encodeId=c90813183e8df, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326479, encodeId=b5ab13264e9c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379358, encodeId=b4c83e9358e2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 17 21:45:45 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893264, encodeId=42841893264c0, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Mar 25 12:48:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854649, encodeId=07c8185464967, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 05 19:48:00 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318378, encodeId=c90813183e8df, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326479, encodeId=b5ab13264e9c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Feb 19 08:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379358, encodeId=b4c83e9358e2, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Feb 17 21:45:45 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-02-17 qingfengqishi5

    学习了,学习了

    0

相关资讯

JACC:细胞外体积分数可独立预测主动脉瓣狭窄患者死亡率

心肌纤维化是主动脉瓣狭窄患者左室失代偿的主要机制,且可用心脏磁共振(CMR)的细胞外体积分数(ECV)进行定量分析。本研究的目的旨在评估ECV%与左室失代偿和主动脉瓣狭窄介入治疗预后指标的相关性。本研究纳入分析了440名接受了CMR检测的重度主动脉瓣狭窄患者(平均年龄70±10岁,男性占59%),ECV%不随扫描仪制造商、磁场强度或T1映射序列的不同而改变。分析结果发现,ECV%与左室失代偿的指标

JACC:心梗会影响主动脉反流患者的二尖瓣生长和功能

二尖瓣环扩大是预防由慢性主动脉反流(AR)所致左室扩张引起的二尖瓣反流,这种扩张在功能性二尖瓣返流患者中是缺乏的,而在缺血性心肌病患者中仍然很常见。本研究提出假设:心梗会损害AR患者瓣叶的生长,并引起二三尖瓣的纤维性改变。本研究对AR、AR+心梗和对照山羊模型进行90天的随访,并通过心脏磁共振、超声心动图和计算机断层扫描于基线水平和随访90天后测量山羊的左室容积、左室功能、二尖瓣反流和二尖瓣叶大小

JACC:PET可以预测心肌淀粉样变性患者的预后

目前,对于心肌淀粉样沉积程度的非侵入性评估是否能预测轻链(AL)心肌淀粉样变性患者的预后尚不清楚。本研究的目的旨在评估11C-PiB PET是否能预测AL心肌淀粉样变性的预后。本研究纳入分析了41名AL心肌淀粉样变性患者,主要终点事件是全因死亡、心脏移植和急性心衰的复合事件。分析结果显示,相比于对照,11C-PiB PET的摄入在心肌淀粉样变性患者中更高,并与免疫组化的淀粉沉积程度相符。在平均42

JACC:经导管肺动脉瓣置换术后不良事件的研究

经导管肺动脉瓣置换术(TPVR)可增加患者操作相关性不良事件(SAE)风险和辐射暴露风险。本研究的目的旨在研究TPVR与SAE和高剂量辐射暴露的相关性和危险因素。本研究纳入分析了530名(男性占59%)接受TPVR治疗的患者,平均年龄为18.3岁,平均体重为58Kg。植入性器械包括同种移植(41%)、生物假体(30%)、自体右心室流出道(27%)和其他(2%),SAE的发生率为13%,其中包括1例

盘点:JACC1月第三期研究一览

1. 双侧胸内动脉搭桥术后的预后研究DOI: 10.1016/j.jacc.2019.11.026http://www.onlinejacc.org/content/75/3/258本研究的目的旨在评估双侧胸内动脉(BITA)搭桥术后优势左前降支(LAD)和重要的非LAD靶血管对冠心病患者预后的影响。本研究纳入分析了6127名接受BITA手术的患者,其中2551名患者接受的是一侧胸内动脉移植至LA

Eur Heart J:房颤患者的体育锻炼、心肺适能与心血管结局

由此可见,较高的PA和CRF与AF患者较低的CVD长期风险和全因死亡率相关。该发现支持AF患者常规PA和改善CRF的作用,以应对死亡率和发病率升高的风险。